Simplex Trading
PTGX icon

Simplex Trading’s Protagonist Therapeutics PTGX Stock Holding History

Simplex Trading’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$503K Sell
4,100
-31,100
-88% -$3.25M ﹤0.01% 3597
2026
Q1 		$3.71M Buy
+35,200
New +$3.12M ﹤0.01% 1334
2025
Q4 		– Sell
-15,700
Closed -$1.04M – 9777
2025
Q3 		$1.04M Buy
15,700
+12,400
+376% +$705K ﹤0.01% 2998
2025
Q2 		$182K Sell
3,300
-9,900
-75% -$475K ﹤0.01% 4611
2025
Q1 		$638K Buy
13,200
+12,400
+1,550% +$520K ﹤0.01% 3134
2024
Q4 		$30K Sell
800
-2,000
-71% -$87.2K ﹤0.01% 6365
2024
Q3 		$126K Sell
2,800
-800
-22% -$32.3K ﹤0.01% 4994
2024
Q2 		$124K Buy
3,600
+700
+24% +$20.5K ﹤0.01% 5144
2024
Q1 		$83K Sell
2,900
-1,500
-34% -$40.8K ﹤0.01% 5778
2023
Q4 		$100K Sell
4,400
-1,900
-30% -$33.2K ﹤0.01% 5387
2023
Q3 		$105K Sell
6,300
-1,300
-17% -$25.2K ﹤0.01% 5038
2023
Q2 		$209K Sell
7,600
-85,800
-92% -$2.15M ﹤0.01% 4249
2023
Q1 		$2.15M Buy
93,400
+65,200
+231% +$1.09M ﹤0.01% 1886
2022
Q4 		$307K Buy
28,200
+5,200
+23% +$43.9K ﹤0.01% 3711
2022
Q3 		$193K Sell
23,000
-14,100
-38% -$133K ﹤0.01% 4661
2022
Q2 		$293K Buy
37,100
+11,900
+47% +$144K ﹤0.01% 4132
2022
Q1 		$596K Buy
25,200
+5,500
+28% +$155K ﹤0.01% 3611
2021
Q4 		$673K Buy
19,700
+18,300
+1,307% +$578K ﹤0.01% 3415
2021
Q3 		$65K Hold
1,400
– – ﹤0.01% 7194
2021
Q2 		$62K Buy
1,400
+1,389
+12,627% +$45.8K ﹤0.01% 7385
2021
Q1 		$28K Buy
11
+10
+1,000% +$253 ﹤0.01% 7189
2020
Q4 		$2K Hold
1
– – ﹤0.01% 7999
2020
Q3 		$1K Buy
+1
New +$19 ﹤0.01% 7586

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Simplex Trading's PTGX Position: Q2 2026 in Review

Simplex Trading opened a new position in Protagonist Therapeutics (PTGX) in Q2 2026: 3,149 shares worth $386K. The stake represents ﹤0.01% of the portfolio and ranks #3933 among its holdings. This is a return to the name: Simplex Trading previously reported a position in PTGX as recently as Q2 2025.

Simplex Trading first reported a position in PTGX in Q4 2020 and has held it in 13 quarters since. The position peaked at $1.45M in Q1 2023. 344 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Simplex Trading held 3,149 shares of Protagonist Therapeutics worth $386K as of Q2 2026.
  • Protagonist Therapeutics was a new Simplex Trading position in Q2 2026.
  • Protagonist Therapeutics made up ﹤0.01% of Simplex Trading's portfolio in Q2 2026, its #3933 holding.
  • Simplex Trading first reported a position in Protagonist Therapeutics in Q4 2020 and has held it in 13 quarters since.
  • Simplex Trading's Protagonist Therapeutics position peaked at $1.45M in Q1 2023.
  • 344 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Simplex Trading's 13F filing for Q2 2026, filed 12 Aug 2026.